Effectiveness of platelet rich plasma in comparison with Triamcinolone Hexacetonide in improving pain and function in patients with de Quervains tenosynovitis: A Randomised controlled trial - Nil

开始日期2024-08-20

申办/合作机构

Regional Institute of Medical Sciences

CTRI/2024/06/069688 / Not yet recruiting临床4期

A Prospective, Multicenter, Open-label, Post-Marketing Observational Study to Evaluate the Effectiveness and Safety of Triamcinolone Hexacetonide Intra-Articular Injection in Adhesive Capsulitis of the Shoulder (Frozen Shoulder) - NIL

开始日期2024-07-09

申办/合作机构

Abbott India Ltd.

NCT06308887 / Completed临床4期IIT

Comparison of the Effectiveness of Ultrasound-Guided Perimeniscal Steroid and Dextrose Injections in Knee Osteoarthritis

Introduction: The primary goal of treating knee osteoarthritis is to reduce pain and improve the patient's quality of life. Medial meniscal extrusion is a condition that is linked to pain and disability in knee osteoarthritis and can be identified through ultrasound. For patients with medial meniscal extrusion, perimeniscal corticosteroid injection has been shown to be a helpful addition to primary treatment for moderate to severe pain relief. Dextrose prolotherapy has also been found to provide periarticular benefits for knee osteoarthritis. This study aims to compare the effectiveness of ultrasound-guided perimeniscal corticosteroid and perimeniscal dextrose injections in patients with osteoarthritis, medial knee pain, and medial meniscal extrusion.
Method: Patients with medial knee pain and meniscal extrusion were randomly divided into two groups using the double-block randomization method. Group 1 included 15 patients who were administered an ultrasound-guided perimeniscal steroid injection, while Group 2 included 16 patients who were administered an ultrasound-guided perimeniscal dextrose injection. The patients' pain levels were evaluated using the Visual Analog Pain Scale (VAS) and the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) before and one week, one month, and three months after the injection.

开始日期2023-10-02

申办/合作机构

Kastamonu University

100 项与己曲安奈德相关的临床结果

登录后查看更多信息

100 项与己曲安奈德相关的转化医学

登录后查看更多信息

100 项与己曲安奈德相关的专利（医药）

登录后查看更多信息

306

项与己曲安奈德相关的文献（医药）

2024-11-16·POSTGRADUATE MEDICINE

Article

作者: Yildirim, Deniz Gezgin ; Bakkaloğlu, Sevcan A. ; Yıldız, Çisem ; Esmeray Şenol, Pelin ; Küçükali, Batuhan ; Kutlar, Merve ; Sunar Yayla, Emine Nur ; Karaçayır, Nihal ; Belder, Nuran

BACKGROUND:

Juvenile idiopathic arthritis (JIA) is a common chronic rheumatic disease in children, requiring careful management to reduce both short- and long-term morbidity. In this study, our objective was to assess the clinical features of patients diagnosed with JIA who received intra-articular corticosteroid injections (IACI).

METHODS:

In this retrospective study, we evaluated the clinical and laboratory characteristics of 225 JIA patients monitored from January 2012 to October 2023 at a tertiary care center. We focused on patients who underwent intra-articular corticosteroid injections (IACI) as part of their treatment. Triamcinolone hexacetonide (TH) was used due to its demonstrated safety and efficacy.

RESULTS:

Our analysis revealed that IACI, particularly utilizing TH, was a widely employed and effective adjunct therapy, contributing to rapid symptom relief and local disease control. Patients receiving IACI exhibited earlier symptom onset, younger age at diagnosis, longer follow-up durations, and higher cumulative treatment burden (p < 0.001, p < 0.001, p < 0.01, p < 0.001 respectively). Despite inconclusive acute-phase reactants, a higher frequency of ANA positivity and elevated initial lymphocyte counts were associated with increased IACI use (p < 0.001, p < 0.001 respectively). Importantly, on a joint basis, a high percentage of arthritis remission following IACI underscores its efficacy and favorable safety profile.

CONCLUSIONS:

Notably, the high percentage of arthritis remission achieved with intra-articular corticosteroid injections (IACI) on a joint-specific basis highlights its efficacy and favorable safety profile. A lymphocyte count exceeding 5000/mm³ at the time of diagnosis may serve as an early indicator for considering intra-articular steroid administration. These findings emphasize the need for nuanced and individualized treatment strategies in JIA management to optimize outcomes for affected children.

2024-11-01·Value in Health Regional Issues

Custo-Efetividade de Diferentes Tratamentos Minimamente Invasivos Para Disfunção Temporomandibular de Origem Articular sob a Perspectiva do Sistema Público de Saúde Brasileiro

Article

作者: da Silva, Pâmela L.P. ; Pereira, Antônio C ; Pereira, Antônio C. ; Moretti, Eduarda C ; Moretti, Eduarda C. ; Lemos, George A ; Lemos, George A. ; da Silva, Pâmela L P

OBJECTIVE:

This study aimed to evaluate the cost-effectiveness (CE) of minimally invasive interventions for pain associated with articular temporomandibular dysfunction from the Brazilian Public Health System (SUS) perspective.

METHODS:

This is a CE study with a 1-year time horizon. Effectiveness data were extracted from a network meta-analysis, and 2 treatments with moderate levels of evidence certainty were evaluated: arthrocentesis (ARTRO) plus intra-articular corticosteroid (CO) injection and ARTRO plus intra-articular injection of sodium hyaluronate (SH). For CE analysis, the costs of 2 types of SH (low and high molecular weight) and 4 COs (betamethasone [B], dexamethasone acetate [D], methylprednisolone sodium succinate [M], or triamcinolone hexacetonide [T]) were considered. Modeling was conducted using TreeAge Pro Healthcare software, with the construction of a decision tree representing a hypothetical cohort of adults with articular temporomandibular dysfunction. Deterministic and probabilistic sensitivity analyses were performed. In addition, an acceptability curve was developed.

RESULTS:

The total costs per joint for ARTRO plus low- and high-molecular-weight SH and ARTRO plus COs B, D, M, and T were, respectively, R$583.32, R$763.85, R$164.39, R$133.93, R$138.57, and R$159.86. ARTRO plus dexamethasone acetate was considered cost-effective, with lower cost and higher net monetary benefit than other technologies. In all sensitivity analysis scenarios, it remained cost-effective. It also showed greater acceptability.

CONCLUSION:

ARTRO plus dexamethasone acetate was considered the cost-effective technology, exhibiting higher net monetary benefit and higher acceptability from the SUS perspective.

2024-10-01·Orthopaedics & Traumatology-Surgery & Research

Article

作者: Jacquet, Christophe ; Mabrouk, Ahmed ; Guenoun, Daphne ; Ollivier, Matthieu ; Onishi, Shintaro ; Cavaignac, Etienne

BACKGROUND:

Degenerative medial meniscus tears are a common pathology in the general population. Recent randomized trials demonstrated non-superiority of arthroscopic partial meniscectomy over conservative management. However, there is a paucity of information regarding the outcomes of combined conservative treatments.

HYPOTHESIS:

It was hypothesized that combined intra- and perimeniscal corticosteroid injections with structured physiotherapy, for degenerative medial meniscus tears, would result in high surgery-free and second injection-free survivorship.

METHODS:

A retrospective review of 671 patients with symptomatic degenerative medial meniscus tears, who received intra- and perimeniscal corticosteroids injection combined with structured physiotherapy, was conducted. An ultrasound-guided injection of Triamcinolone Hexacetonide 20 mg/ml comprised; 1.5 ml intra-meniscal,1.5 ml in the meniscal wall, and 2 ml in the peri-meniscal space, was performed. Surgery free- and a second injection free-survivorship were analysed. Western Ontario and Macmaster University scores (WOMAC), Tegner activity scores, patient satisfaction, return-to-work status and average time to return to work were recorded.

RESULTS:

A total of 481 patients who met the inclusion criteria were included. The mean age was 51.1 ± 7.9 years. At five years post-procedure, surgery-free, and second injection-free survivorship of the ipsilateral knee was 83%, and 52%, respectively. A multivariate analysis adjusting survival on parametric risk factors identified that only effusion before steroid injection was an independent risk factor of treatment failure. At a mean follow-up of 4 ± 2 years, there was an improvement in WOMAC scores by 5.2 ± 4.9 for pain, by 2 ± 2 for stiffness, by 7.3 ± 7.4 for function, and by 12.4 ± 12.7 for the global scores. Additionally, there was significant improvement in the Tegner activity scores (All p < 0.001). Knee effusion and advanced osteoarthritis (Kellgren-Lawrence > III) were significantly associated with poorer outcomes; p < 0.003 and p < 0.0004, respectively.

CONCLUSION:

A combination of intra- and perimeniscal corticosteroid injections and structured physiotherapy for degenerative medial meniscus tears, results in high surgery-free (83%) and second injection-free (52%) survivorship, as well as, effective clinical outcomes and satisfaction at 5 years.

LEVEL OF EVIDENCE:

IV; Retrospective Case Series.

项与己曲安奈德相关的新闻（医药）

2021-06-09

·BioSpace

Medexus Announces Availability of Triamcinolone Hexacetonide in the United States

TORONTO and CHICAGO and MONTREAL, June 09, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) announced today that it is initiating immediate availability of Triamcinolone Hexacetonide Injectable Suspension, USP (20 mg/ml) (TH) in the United States via the U.S. Food and Drug Administration’s (FDA) CDER Drug Shortage program. More information about the FDA’s Drug Shortage program is available at: FDA Drug Shortages. TH is indicated for intra-articular, intrasynovial, or periarticular use in adults and adolescents for the symptomatic treatment of subacute and chronic inflammatory joint diseases, including: rheumatoid arthritis, juvenile idiopathic arthritis (JIA), osteoarthritis and post-traumatic arthritis, synovitis, tendinitis, bursitis and epicondylitis. To address the ongoing shortage of TH in the United States, Medexus is coordinating with Ethypharm, its licensing partner, to generate the data needed to support an Abbreviated New Drug Application (ANDA) filing in an expedited timeframe. About Medexus Medexus is a leading innovative and rare disease company with a strong North American commercial platform. From a foundation of proven best in class products we are building a highly differentiated company with a portfolio of innovative and high value orphan and rare disease products that will underpin our growth for the next decade. The Company’s vision is to provide the best healthcare products to healthcare professionals and patients, through our core values of Quality, Innovation, Customer Service and Teamwork. Medexus Pharmaceuticals is focused on the therapeutic areas of auto-immune disease, hematology, and allergy. The Company’s leading products are: Rasuvo™ and Metoject®, a unique formulation of methotrexate (auto-pen and pre-filled syringe) designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY®, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B – a hereditary bleeding disorder characterized by a deficiency of clotting factor IX in the blood, which is necessary to control bleeding; and Rupall®, an innovative prescription allergy medication with a unique mode of action. For more information, please contact: Ken d’Entremont, Chief Executive Officer Medexus Pharmaceuticals Inc. Tel.: 905-676-0003 E-mail: ken.dentremont@medexus.com Roland Boivin, Chief Financial Officer Medexus Pharmaceuticals Inc. Tel.: 514-344-8765 E-mail: roland.boivin@medexus.com Investor Relations (U.S.): Crescendo Communications, LLC Tel: +1-212-671-1020 Email: mdp@crescendo-ir.com Investor Relations (Canada): Tina Byers Adelaide Capital Tel: 905-330-3275 E-mail: tina@adcap.ca Forward looking and other cautionary statements Certain statements made in this press release contain forward-looking information within the meaning of applicable securities laws (“forward-looking statements”). The words “anticipates”, “believes”, “expects”, “will”, “plans” and similar expressions are often intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Specific forward-looking statements contained in this news release include, but are not limited to, statements with respect to the immediate availability of TH in the United States and the Company’s ability to generate the data needed to support an ANDA filing in an expedited timeframe. These statements are based on factors or assumptions that were applied in drawing a conclusion or making a forecast or projection, including assumptions based on historical trends, current conditions and expected future developments. Since forward-looking statements relate to future events and conditions, by their very nature they require making assumptions and involve inherent risks and uncertainties. The Company cautions that although it is believed that the assumptions are reasonable in the circumstances, these risks and uncertainties give rise to the possibility that actual results may differ materially from the expectations set out in the forward-looking statements. Material risk factors include those set out in the Company’s materials filed with the Canadian securities regulatory authorities from time to time, including the Company’s most recent annual information form and management’s discussion and analysis. Given these risks, undue reliance should not be placed on these forward-looking statements, which apply only as of the date hereof. Other than as specifically required by law, the Company undertakes no obligation to update any forward-looking statements to reflect new information, subsequent or otherwise. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Best in Class

2020-01-07

·SYNAPSE

Ardian sells Riemser to international pharmaceutical company Esteve

Ardian, a world-leading private investment house, has come to an agreement to sell all the shares of the German pharmaceutical company RIEMSER to ESTEVE, an international pharmaceutical company headquartered in Barcelona. Financial details of the transaction will not be disclosed. The closing of the transaction is subject to antitrust approval and is expected in the first quarter of 2020. RIEMSER is a provider of specialty pharmaceuticals in human medicine headquartered in Greifswald and Berlin. The Company has subsidiaries in Great Britain, France and Spain, and an international distribution network across more than 50 countries. With the acquisition of RIEMSER, ESTEVE broadens its access to the fast-growing hospital market, in which RIEMSER is particularly successful. Today, RIEMSER generates about 80 percent of its sales with products for clinical application. Numerous RIEMSER drugs are considered ‘gold standard’. Ardian acquired RIEMSER in 2012 and, together with the management team, successfully refocused the company on its core business of specialty pharmaceuticals, which it acquires, licenses, markets and distributes. Today, the company’s product portfolio comprises prescription drugs for the treatment of serious diseases in oncology, neurology, infectiology, as well as niche indications in cardiovascular medicine, dermatology, rheumatology and infectiology. RIEMSER has divested from areas which are not part of its core business, such as the dental and veterinary business and the medical devices business. The proceeds were invested in the licensing and acquisition of products, the acquisition of companies in the specialty pharmaceuticals sector and the expansion of indications for existing products: RIEMSER acquired Keocyt in France in 2014 and Intrapharm, based in England, in 2015. In 2016, the acquisition of the CNS division of Dolorgiet followed, whose products expanded the portfolio by the therapeutic area of neurology. In 2019, RIEMSER bought the Spanish distribution service provider Zaltanpharma, which has since been renamed RIEMSER Iberia. In the area of drug approval and in--licensing, RIEMSER, among others introduced the active ingredient triamcinolone hexacetonide in Canada and concluded an agreement with the Japanese pharmaceutical company Eisai on the exclusive development and marketing rights for Prialt in Europe in 2018; in 2019 Keocyt received a new EU approval for Zanosar in eleven European countries. Christof Naményi, Managing Director in the German Ardian Buyout team, said: "Ardian has extensive experience as an investor in the European healthcare, life sciences and pharmaceutical markets. We are pleased that we have been able to successfully leverage our expertise and network with RIEMSER, supporting the company’s acquisition strategy, corporate and organisational development, and executive recruitment. We would like to thank Konstantin von Alvensleben, his management team and all RIEMSER employees for the excellent cooperation and wish them all the best for the future.” Konstantin von Alvensleben, CEO of RIEMSER, added: "When I joined RIEMSER in 2015, Ardian had already set the course for the further development of the company. I am pleased that since then we have been able to accelerate this process and together reached further milestones in the growth and internationalisation of the business. Ardian’s support was invaluable in achieving this. We are very proud that with Esteve, a strong family-owned pharma company with a long tradition, has chosen to acquire Riemser and we are looking forward to entering the next stage of our development. Being part of a much larger Group will support our joint growth. "

上市批准并购引进/卖出

100 项与己曲安奈德相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00985	己曲安奈德	R01AD11 H02AB08 S01BA05	DBSALT000861

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
类风湿关节炎	加拿大	Medexus, Inc.	2017-12-12
斑秃	美国	Sandoz, Inc.	1969-07-29
环形肉芽肿	美国	Sandoz, Inc.	1969-07-29
瘢痕疙瘩	美国	Sandoz, Inc.	1969-07-29
盘状红斑狼疮	美国	Sandoz, Inc.	1969-07-29
类脂质渐进性坏死	美国	Sandoz, Inc.	1969-07-29
神经性皮炎	美国	Sandoz, Inc.	1969-07-29
斑块状银屑病	美国	Sandoz, Inc.	1969-07-29

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ACR2020	N/A	幼年特发性关节炎一线	102	Triamcinolone hexacetonide	觸顧衊鹹廠顧鹽齋鏇獵(糧艱醖艱獵淵鑰醖網糧) = 鬱願壓觸顧鏇齋網襯餘淵簾鑰選鏇選蓋構齋衊 (膚憲廠鹽鹹襯顧壓醖製 ) 更多	积极	2020-11-07
				Triamcinolone acetonide	觸顧衊鹹廠顧鹽齋鏇獵(糧艱醖艱獵淵鑰醖網糧) = 鬱製憲廠鹹夢築願衊鬱淵簾鑰選鏇選蓋構齋衊 (膚憲廠鹽鹹襯顧壓醖製 ) 更多
NCT01770912 (CTgov)	临床2期	疼痛	24	Lactated Ringers (Lactated Ringers)	願夢壓廠襯鬱鹽繭齋窪(願鹹積構簾築鹹糧鏇蓋) = 膚顧鑰膚襯簾鬱積觸繭糧積膚廠願膚廠遞醖壓 (獵衊憲選憲築憲艱夢餘, 顧襯願鹹製觸積鏇蓋鏇 ~ 構齋積製衊艱製鏇衊鏇) 更多	-	2020-10-08
				Triamcinolone hexacetonide (Triamcinolone Acetonide)	願夢壓廠襯鬱鹽繭齋窪(願鹹積構簾築鹹糧鏇蓋) = 衊網餘齋夢襯蓋鹽憲壓糧積膚廠願膚廠遞醖壓 (獵衊憲選憲築憲艱夢餘, 壓憲醖積壓構顧衊艱鑰 ~ 襯築衊餘築遞壓淵齋蓋) 更多
EUCTR2014-000993-20-SE \| NCT02437461 (Pubmed \| Scand J Rheumatol)	临床4期	膝关节滑膜炎 \| 多发性关节炎	159	20 mg THA	蓋鏇齋遞蓋鑰夢繭膚範(衊繭網鏇積餘鹹餘蓋獵) = 網網糧餘蓋鑰淵鏇選鏇遞獵築鏇鹽鹹蓋醖壓鬱 (範積選糧衊窪遞鬱艱憲 )	-	2019-07-01
				40 mg THA	蓋鏇齋遞蓋鑰夢繭膚範(衊繭網鏇積餘鹹餘蓋獵) = 糧夢壓觸網積鑰壓夢願遞獵築鏇鹽鹹蓋醖壓鬱 (範積選糧衊窪遞鬱艱憲 )
EULAR2018	N/A	膝关节滑膜炎	159	20 mg triamcinolone hexacetonide	糧顧繭艱簾觸糧觸網膚(襯餘蓋襯衊糧鬱鑰鹽鹹) = 鹽餘膚鏇齋淵選網蓋醖選繭齋觸鹹鬱淵鏇艱艱 (餘夢襯選鹹醖餘鏇艱艱 )	-	2018-06-13
				40 mg triamcinolone hexacetonide	糧顧繭艱簾觸糧觸網膚(襯餘蓋襯衊糧鬱鑰鹽鹹) = 餘衊鹽繭範衊製壓淵醖選繭齋觸鹹鬱淵鏇艱艱 (餘夢襯選鹹醖餘鏇艱艱 )
EULAR2014	N/A	风湿性疾病	-	Triamcinolone hexacetonide intra-articular injection	窪蓋築顧範遞夢積淵範(願壓觸築繭獵夢壓壓築) = 衊鏇膚鬱製窪簾糧鏇製夢選齋夢衊範淵餘襯遞 (獵窪夢夢築艱艱壓襯夢 )	-	2014-06-11
EULAR2012	N/A	关节炎	27	Triamcinolone hexacetonide	淵顧簾網積壓顧齋糧願(網餘選蓋膚窪壓觸壓膚) = 膚齋願廠齋餘艱衊鑰蓋壓廠鬱鏇鹹積衊獵襯壓 (網築醖襯鬱願築餘製範 ) 更多	积极	2012-06-06
EULAR2010	N/A	关节炎	15	Triamcinolone hexacetonide	衊選繭鹹淵範壓廠顧範(齋範簾獵獵齋簾蓋鬱夢) = 窪鑰艱壓願襯選廠製襯夢窪鹹壓憲蓋製顧網憲 (膚構簾鏇窪顧餘網餘鏇, 14.29) 更多	-	2010-06-16
EULAR2002	N/A	幼年特发性关节炎 anti-nucleus antibodies (ANA) \| B CD5+ lymphocytes \| T gamma/delta+ lymphocytes	37	Intra-articular Triamcinolone Hexacetonide	蓋膚選獵廠鬱選鏇膚鏇(壓顧淵餘壓蓋襯繭糧齋) = 網廠築夢製觸夢願簾膚鹽鹽憲選顧範齋選蓋壓 (願憲淵鹹觸襯選顧齋襯 ) 更多	积极	2002-06-12